News | January 13, 2025
Aragen secures $100 million investment from Quadria Capital
Investment will fund expansion to meet rising demand for CRDMO services
Investment will fund expansion to meet rising demand for CRDMO services
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
The site’s GMP Certification has been successfully renewed
Increases speed to market for drug developers working on nucleic acid therapeutics
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Subscribe To Our Newsletter & Stay Updated
